ABVC · NASDAQ
ABVC BioPharma (ABVC) Stock Price & Fundamentals
ABVC BioPharma (ABVC) closed at $407.94 on Oct 9, 2026, down 0.30% from the previous close of $409.18.
Share price, past year
1Y +15.61%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $407.94 |
| Sep 30, 2026 | $415.62 |
| Aug 31, 2026 | $428.38 |
| Jul 31, 2026 | $402.30 |
| Jun 30, 2026 | $387.34 |
| May 29, 2026 | $380.16 |
| Apr 30, 2026 | $391.49 |
| Mar 31, 2026 | $392.35 |
| Feb 27, 2026 | $374.61 |
| Jan 30, 2026 | $381.22 |
| Dec 31, 2025 | $391.62 |
| Nov 28, 2025 | $375.29 |
| Oct 31, 2025 | $350.51 |
Key statistics
- Market cap
- $10.51B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.29
- Revenue (TTM)
- —
- Net income (TTM)
- −$7.11M
- Shares outstanding
- 25.8M
- Dividend yield
- —
- 52-week range
- $344.84 – $430.95
ABVC BioPharma's market cap is $10.51B, based on a share price of $407.94 and 25.8M shares outstanding as of Jun 30, 2026.
Financials
ABVC BioPharma reported revenue of $296.00K for fiscal 2025, down 41.91% from fiscal 2024.
ABVC BioPharma reported a net loss of $7.91M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $296.00K | −41.9% | −$7.91M | −2,671.8% | −$0.39 | — |
| FY2024ended Dec 31, 2024 | $509.59K | +234.3% | −$4.90M | −962.1% | −$0.42 | — |
| FY2023ended Dec 31, 2023 | $152.43K | −84.3% | −$7.79M | −5,109.3% | −$1.80 | −$4.21M |
| FY2022ended Dec 31, 2022 | $969.78K | +172.6% | −$16.42M | −1,693.5% | −$5.19 | −$7.52M |
| FY2021ended Dec 31, 2021 | $355.80K | −26.3% | −$12.84M | −3,608.5% | −$0.51 | −$7.62M |
| FY2020ended Dec 31, 2020 | $483.05K | −31.2% | −$10.59M | −2,193.1% | −$0.50 | — |
| FY2019ended Dec 31, 2019 | $701.72K | +9,988.0% | −$3.93M | −560.5% | −$0.21 | — |
| FY2018ended Dec 31, 2018 | $6.96K | +107.0% | −$6.06M | −87,184.2% | −$0.02 | — |
| FY2015ended Sep 30, 2015 | $3.36K | −56.9% | — | — | — | — |
| FY2013ended Sep 30, 2013 | $7.79K | — | — | — | — | −$37.77K |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2025ended Sep 30, 2025 | $795.95K | −$2.04M | −$0.09 |
| Q4 FY2024ended Dec 31, 2024 | $1.97K | −$731.57K | −$0.02 |
| Q3 FY2024ended Sep 30, 2024 | $389.28K | −$394.77K | −$0.03 |
| Q2 FY2024ended Jun 30, 2024 | $117.14K | — | — |
| Q1 FY2024ended Mar 31, 2024 | $1.21K | — | — |
| Q4 FY2023ended Dec 31, 2023 | $2.17K | — | — |
| Q3 FY2023ended Sep 30, 2023 | $15.88K | — | — |
| Q2 FY2023ended Jun 30, 2023 | $6.11K | — | — |
Company profile
- Name
- ABVC BioPharma, Inc.
- Ticker
- ABVC
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 44370 Old Warm Springs Blvd., Fremont, CA 94538
- Incorporated in
- NV
- Fiscal year ends
- December
- SEC CIK
- 0001173313
Recent SEC filings
- Aug 27, 2026
- Aug 12, 2026
- Aug 4, 2026
- Jul 2, 2026
- May 18, 2026
- Mar 27, 2026
- Mar 3, 2026
- Mar 3, 2026
Frequently asked questions
What is ABVC BioPharma's stock price?
ABVC BioPharma (ABVC) closed at $407.94 on Oct 9, 2026, down 0.30% from the previous close of $409.18.
What is ABVC BioPharma's market cap?
ABVC BioPharma's market cap is $10.51B, based on a share price of $407.94 and 25.8M shares outstanding as of Jun 30, 2026.
How much revenue does ABVC BioPharma make?
ABVC BioPharma reported revenue of $296.00K for fiscal 2025, down 41.91% from fiscal 2024.
Does ABVC BioPharma pay a dividend?
ABVC BioPharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from ABVC BioPharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures